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clinical response in proof-of-concept trials in axial
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Introduction: Biomarkers complementing clinical evaluations may help to reduce the length and size of
proof-of-concept (PoC) trials aimed to obtain quick “go/no go” decisions in the clinical development of new
treatments. We aimed to identify and validate serum biomarkers with a high sensitivity to change upon effective
treatment in spondyloarthritis (SpA) PoC trials.
Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), pentraxin-3
(PTX-3), alpha-2-macroglobulin (alpha-2-MG), matrix metalloproteinase-3 (MMP-3), calprotectin, and vascular
endothelial growth factor (VEGF) were determined by enzyme-linked immunosorbent assay (ELISA) in healthy
controls (n = 20) and SpA patients before and after 2 weeks of infliximab (n = 18) or placebo (n = 19) treatment in
cohort 1. Clinical outcome was evaluated at week 12. Results were validated in ankylosing spondylitis (AS) with
infliximab (cohort 2, n = 21) and peripheral SpA with etanercept (cohort 3, n = 20).
Results: Serum levels of calprotectin, hs-CRP, PTX-3, VEGF (all P < 0.001) and MMP-3 (P = 0.062), but not IL-6 and
alpha-2-MG, were increased in SpA versus healthy controls. Treatment with infliximab, but not placebo, significantly
decreased calprotectin (P < 0.001) and hs-CRP (P < 0.001) levels, with a similar trend for MMP-3 (P = 0.063). The
standardized response mean (SRM), which reflects the ability to detect changes over time, was high for calprotectin
(−1.26), good for hs-CRP (−0.96) and moderate for MMP-3 (−0.52). Calprotectin and hs-CRP, but not MMP-3, were
good biomarkers for treatment response in axial and peripheral SpA as evaluated and confirmed in cohort 2 and
3 respectively.
Conclusions: Calprotectin and hs-CRP are good serum biomarkers with high sensitivity to change upon effective
treatment at the group level in small-scale, short term PoC trials in SpA.Introduction
The use of tumor necrosis factor (TNF) blockers has
dramatically improved the clinical outcome and quality of
life of patients with spondyloarthritis (SpA). Originally
implemented in ankylosing spondylitis (AS) and psoriatic
arthritis (PsA), there is now increasing evidence that
they are equally effective in other subtypes such as
non-radiographic axial SpA and non-AS, non-PsA per-
ipheral SpA [1-6]. Nevertheless, TNF blockade in SpA still* Correspondence: d.l.baeten@amc.uva.nl
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stated.has important limitations. First, contraindications and side
effects, especially in patients with severe comorbidity, pre-
clude the use of TNF blockers in a significant proportion
of SpA patients. Second, TNF blockade fails to fully
control signs and symptoms of disease in a significant
proportion of patients, with only 15 to 20% reaching
partial remission [1-6]. Third, the currently available
evidence suggests that TNF blockade fails to halt new
bone formation and ankylosis [7]. Finally, TNF blockade
fails to induce long-lasting drug-free remission as
disease relapses within a few months of treatment inter-
ruption in a large majority of patients [8,9].
These limitations indicate that there is still an important
unmet medical need for alternative treatment options in
SpA. However, the success of TNF blockade also raisestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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long-term, placebo-controlled trials with novel drugs.
Additional strategies to obtain quick go and no-go signals
in small short-term proof-of-concept (PoC) trials before
proceeding to large long-term clinical studies are thus
required. Such tools may comprise biomarkers that
reliably show high sensitivity to change upon clinical
response at the group level. A biomarker is a ‘character-
istic that can be objectively measured and evaluated as
an indicator of a normal biologic process, a patho-
physiologic process, or a pharmacologic response to a
therapeutic intervention’ [10]. If sensitive and repro-
ducible, changes in biomarker levels during treatment
may thus help to substantiate a genuine effect on
specific biological processes in PoC trials.
Several biomarkers have previously been directly or
indirectly associated with treatment response in SpA. C-
reactive protein (CRP) is known to be elevated in active
disease and to decrease upon effective treatment in SpA,
but is less useful than in rheumatoid arthritis (RA) as
two thirds of the SpA patients have normal CRP levels
[11-14]. IL-6 is the main driver of CRP; serum IL-6 levels
are significantly increased in active SpA and decrease
upon clinical response after TNF blockade [15,16]. Al-
though CRP belongs to the short pentraxins, the pentraxin
family also contains long pentraxins, including pentraxin-
3 (PTX-3), which have been proposed as biomarkers of
inflammation [17]. Alpha-2-macroglobulin (alpha-2-MG)
is another CRP-independent acute-phase response protein
that is used as serum biomarker [18].
Besides acute-phase response proteins, several poten-
tial biomarkers have been identified based on their
involvement in the immunopathology of SpA. Matrix
metalloproteinase-3 (MMP-3) levels are associated with
peripheral arthritis, disease activity, progression of struc-
tural damage and response to TNF inhibition in SpA
[19-21]. Calprotectin, a heterodimer consisting of S100A8
and S100A9 (previously called myeloid-related protein
(MRP) 8 and 14, respectively), is expressed and secreted
during monocyte infiltration into inflamed tissues, includ-
ing macrophage infiltration in SpA synovitis [22-24]. Cal-
protectin serum levels are elevated in SpA, correlate well
with disease activity and decrease upon TNF blockade
[23]. Finally, SpA synovitis is characterized by pronounced
hypervascularity [25,26] which is at least in part mediated
by vascular endothelial growth factor (VEGF). VEGF
serum levels are elevated and correlate well with inflam-
mation and disease activity in SpA [27,28].
In this study, we aimed to systematically assess the value
of these serum proteins as biomarkers of effective treat-
ment in PoC trials with TNF blockers in SpA. More spe-
cifically, we aimed to identify which of these serum
proteins can best discriminate between anti-TNF treatment
and placebo as early as 2 weeks after start of treatment.Methods
Patients and samples
Serum samples and clinical data for 20 healthy controls
(HCs) and 78 SpA patients fulfilling the European Spon-
dylarthropathy Study Group (ESSG) [29] criteria were
retrieved from our arthritis biobank for this analysis ac-
cording to the study protocol as approved by the Medical
Ethics Committee of the Academic Medical Center/
University of Amsterdam (2013_057). The SpA population
consisted of three separate cohorts, where cohorts 2
and 3 are considered as independent validation cohorts.
Cohort 1 consisted of 18 SpA patients with AS (n = 8),
PsA (n = 8) and undifferentiated spondyloarthritis (USpA)
(n = 2), who received infliximab (5 mg/kg intravenously)
and 19 SpA patients with AS (n = 9), PsA (n = 9) and
USpA (n = 1), who received placebo at weeks 0, 2 and 6
[1]. Cohort 2 consisted of 21 patients with AS according
to the modified New York criteria, treated with infliximab
(5 mg/kg intravenously) at weeks 0, 2 and 6 [30]. Cohort 3
consisted of 20 patients with peripheral SpA treated with
etanercept (25 mg subcutaneously bi-weekly) [31]. None
of the patients had been previously treated with a TNF
blocker. Serum was obtained at baseline and week 2 for
the first two cohorts, and at baseline and week 4 for
cohort 3. The complete description of these cohorts and
the response to treatment was reported previously
[1,30,31].Serum biomarkers
We determined the serum levels of the following candidate
biomarkers by ELISA as indicated by the manufacturers:
high-sensitivity (hs)-CRP (Research & Diagnostic Systems,
Inc. Minneapolis), IL-6 (Research & Diagnostics Sys-
tems, Inc.), PTX-3 (Research & Diagnostic Systems,
Inc.), alpha-2-MG (Abcam, Cambridge, UK), MMP-3
(Biotrak, Amersham Pharmacia Biotech, Buckinghamshire,
UK), VEGF (Research & Diagnostics Systems, Inc.), and
Calprotectin (Hycult Biotech, the Netherlands). All assays
were performed in duplicate.Statistical analysis
Data were represented as mean (standard error of the
mean) and compared using the parametric t-test (paired
where appropriate) using GraphPad Prism software ver-
sion 5.01. A P-value below 0.05 was considered statisti-
cally significant. The standardized response mean (SRM)
was calculated as the mean change in a parameter in a
defined period of time divided by the SD of that change.
An SRM below 0.5, between 0.5 and 0.8, and above 0.8
indicates a poor, moderate and good potential to detect
changes over time, respectively [32]. Power calculations to
attain 90% power with a significance level of 0.05 were
performed using nQuery Advisor version 7.0 software.
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Baseline serum biomarkers in SpA versus HCs
We first assessed which serum biomarkers were in-
creased in active SpA compared to HCs using the base-
line samples of cohort 1 (Figure 1), assuming that serum
biomarkers that are increased in active disease could
potentially be modulated and normalized by effective
treatment. We thus used this strategy to select bio-
markers of interest; it was not the aim to identify
markers with a high diagnostic discriminative capacity
between SpA and HCs. The serum levels of hs-CRP
(16.44 ± 2.36 μg/ml versus 0.84 ± 0.27 μg/ml; P <0.001),
PTX-3 (271.4 ± 35.0 pg/ml versus 46.0 ± 23.6 pg/ml;
P <0.001), calprotectin (1.76 ± 0.13 μg/ml versus 0.65 ±
0.10 μg/ml; P <0.001) and VEGF (237.0 ± 30.3 pg/mlFigure 1 Serum biomarker levels in active spondyloarthritis (SpA) (n =
t-tests were performed. Data are represented as mean (standard error of th
interleukin-6; PTX-3, pentraxin-3; alpha-2-MG, alpha-2-macroglobulin; MMP-versus 16.7 ± 5.7 pg/ml; P <0.001) were significantly
higher in active SpA versus HCs, with a similar trend
for MMP-3 (0.96 ± 0.21 μg/ml versus 0.29 ± 0.04 μg/ml;
P = 0.062). In contrast, levels of alpha-2-MG and IL-6
were not significantly different between active SpA and
HCs. Elevated serum levels, defined as greater than the
mean + 2 SD of the serum levels of HCs, were observed in
86% of the SpA patients for calprotectin, 82% for VEGF,
81% for hs-CRP, 74% for MMP-3 and 59% for PTX-3.
Short-term modulation of serum biomarkers by infliximab
in SpA
We next assessed which of these biomarkers were sig-
nificantly downregulated by infliximab but not placebo
treatment as early as two weeks after initiation of37) versus healthy controls (HC) (n = 20). Independent samples
e mean). *P <0.05. hs-CRP, high-sensitivity C-reactive protein; IL-6,
3, matrix metalloproteinase-3; VEGF, vascular endothelial growth factor.
Turina et al. Arthritis Research & Therapy 2014, 16:413 Page 4 of 9
http://arthritis-research.com/content/16/4/413therapy. We previously reported that both arms of this
cohort were well-randomized for disease activity (as
judged by parameters such as patient’s and physician’s glo-
bal assessment of disease activity and Bath ankylosing
spondylitis disease activity index (BASDAI), and that there
was a significant decrease in these parameters during
treatment with infliximab but not placebo [1]. Serum
levels of the investigated biomarkers were similar at base-
line between the infliximab and placebo arms of cohort 1
(Figure 2). In the placebo group, none of the serum
biomarkers changed significantly between baseline and
week 2 (Figure 2). In contrast, we observed a significantFigure 2 Changes in serum biomarkers between baseline (week 0) an
treatment in active spondyloarthritis (SpA). Paired t-tests were perform
*P <0.05. hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; PTX-3
metalloproteinase-3; VEGF, vascular endothelial growth factor.decrease in serum levels of hs-CRP (P <0.001), IL-6
(P = 0.047), and calprotectin (P <0.001) after two weeks of
infliximab treatment, with a similar trend for MMP-3
(P = 0.063) (Figure 2). Levels of PTX-3, alpha-2-MG and
VEGF were not significantly modulated by infliximab over
this period.
Potential of serum biomarkers to change sensitively upon
active treatment in SpA
As the previous analyses identified calprotectin, hs-CRP, IL-
6 and MMP-3 as the most promising biomarkers of treat-
ment response, we next assessed their potential to changed week 2 of infliximab (IFX) (n = 18) versus placebo (PLC) (n = 19)
ed. Data are represented as mean (standard error of the mean),
, pentraxin-3; alpha-2-MG, alpha-2-macroglobulin; MMP-3, matrix
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ability to detect changes over time [32]. The SRM in the
infliximab group was −1.26 for calprotectin, −0.96 for
hs-CRP, −0.56 for IL-6, and −0.52 for MMP-3. In com-
parison, the SRM in the placebo group was −0.20 for
calprotectin, −0.13 for hs-CRP, −0.05 for IL-6, and 0.23
for MMP-3. Thus, the delta SRM (SRM of active treat-
ment minus SRM of placebo) were −1.06 for calprotec-
tin, −0.83 for hs-CRP, −0.51 for IL-6, and −0.75 for
MMP-3. As calprotectin and hs-CRP correlated moder-
ately (r = 0.648), we next aimed to confirm that an early
change in calprotectin levels is superior to CRP as a bio-
marker of clinically effective treatment by performing a
power analysis on the data of cohort 1. Demonstration
of a significant difference between infliximab and pla-
cebo treatment using changes in calprotectin levels over
two weeks as the outcome parameter with a power of
90% and a significance level of 0.05 would require 15
patients per group. A similar analysis with CRP would
require 24 patients per group. Finally, we determined if
a combination of changes in calprotectin and hs-CRP
levels would be superior in treatment response compared
to changes in calprotectin alone. Changes in calprotectin
levels are independently associated to treatment response
but when combined with changes to hs-CRP levels the as-
sociation to treatment response was no longer significant.Figure 3 Changes in serum biomarker levels between baseline (week
spondylitis (AS) patients (n = 8) (A) and psoriatic arthritis (PsA) patien
2, who did not have peripheral disease (n = 21) (C). Paired t-tests were
mean). *P <0.05. hs-CRP, high-sensitivity C-reactive protein; MMP-3, matrix mSerum biomarkers of active treatment in AS
Cohort 1 consisted of different SpA subtypes, mainly AS
and PsA. To ascertain that the biomarker findings are not
biased by the SpA subtype and that the data can be ex-
trapolated to more homogenous SpA study populations,
we performed two additional sets of analysis. First, we rea-
nalyzed the biomarker data of cohort 1 separately for AS
(n = 8 in the infliximab group and n = 9 in the placebo
group) and PsA (n = 8 in the infliximab group and n = 9 in
the placebo group). In the AS group, only hs-CRP (P =
0.006) and calprotectin (P = 0.028) decreased significantly
after two weeks of infliximab treatment (Figure 3A). De-
creases in IL-6 and MMP-3 levels were not significant
and none of the biomarkers changed in the placebo arm
(data not shown). The SRM was −0.98 for calprotectin
and −1.39 for hs-CRP. For PsA patients, only calprotec-
tin (P = 0.003) decreased significantly after two weeks of
infliximab treatment, with a similar but non-significant
trend for hs-CRP (P = 0.071) (Figure 3B). None of the
biomarkers changed in the placebo arm (data not shown).
The SRM in PsA patients was −1.58 for calprotectin
and −0.75 for hs-CRP.
Second, we performed a similar biomarker analysis in
an independent cohort of patients with AS without per-
ipheral arthritis or enthesitis (n = 20) receiving infliximab
at weeks 0, 2 and 6 (cohort 2). As shown in Figure 3C,0) and week 2 of infliximab treatment in the ankylosing
ts (n = 8) (B) of cohort 1 as well as in the AS patients from cohort
performed. Data are represented as mean (standard error of the
etalloproteinase-3.
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levels decreased significantly after two weeks of infliximab
treatment. MMP-3 (P = 0.093) showed a similar but non-
significant trend in this cohort. The SRM was −0.56 for
calprotectin and −0.59 for hs-CRP. Taken together, these
data indicate that changes in calprotectin and hs-CRP
serum levels reflect well the response to active treatment
with infliximab in AS.
Serum biomarkers of treatment response in peripheral SpA
The previous analyses suggest that there may be some
differences in serum biomarkers between AS and PsA.
To confirm and extend these data and to ascertain that
these biomarkers do not only reflect response to infliximab
but also other TNF inhibitors, we analyzed changes in
serum biomarkers between baseline and week 4 of etaner-
cept treatment in patients with peripheral SpA (cohort 3).
As shown in Figure 4, we again observed a significant de-
crease in serum levels of calprotectin (P = 0.032), hs-CRP
(P = 0.035) and MMP-3 (P = 0.045). In this cohort, the
SRM was −0.55 for calprotectin, −0.54 for hs-CRP,
and −0.51 for MMP-3. Furthermore, changes in calprotec-
tin levels were not influenced by the presence of psoriasis.
Calprotectin as a biomarker in CRP-negative patients
Both calprotectin and CRP are not highly specific to SpA
and are elevated in several diseases. In SpA, CRP levels
were not elevated in two thirds of the patients. Further-
more, the correlation between CRP and calprotectin was
modest in SpA (r = 0.634), suggesting that calprotectin
may provide more or additional information in compari-
son with CRP. We analyzed whether calprotectin is of
additional value by determining the sensitivity to change
upon treatment effect in CRP-negative patients. We there-
fore stratified for CRP status (positive or negative), using
the threshold for normal values from our local laboratory.
For cohort 1, the delta calprotectin levels were −0.30 ±
0.21 μg/ml in CRP-negative patients versus −0.90 ± 0.13
μg/ml in CRP-positive patients, with a corresponding SRM
of −0.79 and −1.60 in CRP-negative and CRP-positive
patients respectively. For cohort 2, the delta calprotectin
levels were −0.19 ± 0.14 μg/ml in CRP-negative patientsFigure 4 Changes in serum biomarkers between baseline (week 0) an
spondyloarthritis (SpA). Paired t-tests were performed. Data are represen
high-sensitivitivity C-reactive protein; MMP-3, matrix metalloproteinase-3.versus −0.35 ± 0.15 μg/ml in CRP-positive patients, with a
corresponding SRM of −0.38 and −0.81 in CRP-negative
and CRP-positive patients respectively. For cohort 3, the
delta serum calprotectin levels were −0.10 ± 0.11 μg/ml
in CRP-negative patients versus −0.30 ± 0.18 μg/ml in
CRP-positive patients, with a corresponding SRM of −0.35
and −0.66 in CRP-negative and CRP-positive patients
respectively.
Discussion
Tissue inflammation is one of the major features of both
axial and peripheral SpA but remains difficult to quan-
tify and monitor in an objective and reliable way in clin-
ical research. The most commonly used biomarkers for
inflammation in SpA are magnetic resonance imaging
(MRI) and CRP. MRI is able to visualize inflammatory
lesions such as synovitis, enthesitis and bone marrow
edema in axial and peripheral SpA and these lesions de-
crease or even disappear upon effective treatment [33,34].
Accordingly, MRI is now used as a measure of inflamma-
tion in clinical trials in AS and axial SpA. However, even
in patients with high clinical disease activity MRI scores
are often low, which makes it difficult to detect significant
pre- and post-treatment changes in small PoC trials [35].
The second widely used measure of inflammation in SpA
is CRP. CRP levels do correlate at the group level with
clinical disease activity, decrease upon effective treatment
and are included in the ankylosing spondylitis disease ac-
tivity score (ASDAS) [36]. As for MRI, however, an im-
portant issue is that baseline serum levels of CRP are
elevated only in a fraction of patients with active SpA, hs-
CRP may therefore perform better than classical CRP
measurements [13,37].
In the current study we explored the value of different
candidate serum biomarkers of clinical response in SpA,
thereby focusing specifically on small, short-term PoC
trials. We aimed to identify serum proteins that are
significantly modulated by effective treatment with TNF
blockers but not by placebo, as early as 2 weeks after
treatment initiation. In line with the previously discussed
data, we found that hs-CRP is a useful biomarker of in-
flammation in this context as, despite not being elevatedd week 4 of etanercept treatment (n = 20) in peripheral
ted as mean (standard error of the mean). *P <0.05. hs-CRP,
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decrease in both axial and peripheral SpA treated with
either infliximab or etanercept. The high SRM and the
absence of changes in the placebo-treated patients con-
firm its value as a biomarker of inflammation in PoC tri-
als. Interestingly, serum levels of IL-6, the major driver of
CRP, did not appear to be a reliable marker of treatment
response in our study. Moreover, two recent clinical trials
with IL-6-receptor blockers failed to demonstrate clinical
efficacy in AS [38,39]. Taken together, these data suggest
that, even though CRP may be used as biomarker, the IL-
6-CRP axis is not a pivotal inflammatory pathway in SpA.
The major finding of the study is that serum levels of
calprotectin appeared to be the most robust and reliable
marker of treatment response in both axial and periph-
eral SpA, even outperforming hs-CRP in some analyses.
For example, a power calculation in the infliximab co-
hort indicated that the use of calprotectin rather than
hs-CRP as biomarker for inflammation would allow sig-
nificant reduction in the size of the cohort. In contrast
to CRP, there is also clear evidence that calprotectin dir-
ectly reflects key inflammatory processes in SpA. Cal-
protectin is produced by myeloid cells and neutrophils
and is secreted when these cells transmigrate through
the endothelium to the inflamed tissues. Elevated levels
of calprotectin as measured in synovial fluid in arthritis
or in the feces in inflammatory bowel disease thus reflect
local tissue infiltration by myeloid cells [40,41]. We and
others have demonstrated that calprotectin is released lo-
cally in SpA synovitis, that the degree of synovial infiltra-
tion with myeloid cells and neutrophils reflect disease
activity in peripheral SpA, and that effective treatment of
peripheral SpA is associated with a rapid and robust de-
crease of calprotectin-positive cells in the inflamed syno-
vium [22-24,42]. In contrast, much less is known about
calprotectin expression in axial disease. Taken together,
these data indicate that secretion of calprotectin may be a
good reflection of local migration and activation of inflam-
matory innate immune cells in target tissues of SpA. Ac-
cordingly, a decrease in these calprotectin levels upon
treatment is likely to reflect a genuine biological effect on
chronic tissue inflammation.
Although we used only TNF blockers as effective
drugs in the present study, we now have evidence that
the biomarker value of calprotectin is not restricted to
this sole mode of action. In a recent PoC study with the
monoclonal anti-IL17A antibody, secukinumab, we dem-
onstrated that both CRP and S100A8 and A9 levels de-
creased rapidly in the treated patients [35]. Supporting
the concept that calprotectin may have additive value
compared to CRP, changes between baseline and week 6
levels of S100A8 and A9, but not CRP, correlated with as-
sessment of spondyloarthritis 20 (ASAS20) and ASAS40
responses at week 6. Moreover, baseline levels of S100A8and S100A9 but not CRP had a high sensitivity to change
upon clinical response to treatment in this trial.
The combination of calprotectin and hs-CRP as bio-
markers for clinical response, does not give any additional
value compared to calprotectin alone. In contrast to cal-
protectin and hs-CRP, the other candidate biomarkers did
not perform that well in our studies. In line with previous
reports [16,20,28,43], serum levels of markers such as
VEGF and MMP-3 did decrease upon effective anti-
inflammatory therapy but the treatment effects were either
smaller or less consistent across different SpA subtypes
and cohorts in comparison with calprotectin and hs-CRP.
This may also be due to the specific setting of the present
study where we aimed to detect very early changes (at
week 2) in biomarker levels.
It is important to emphasize here that our data certainly
do not imply that serum biomarkers such as calprotectin
or hs-CRP should replace clinical outcome parameters. In-
deed, clinical outcomes (including composite indices such
as BASDAI and ASDAS) can also show significant and
rapid changes in anti-TNF treated patients. However, the
correlation between a serum biomarker such as calprotec-
tin and clinical outcomes such as BASDAI is significant
but weak (r = 0.325), indicating that both measurements
do not cover exactly the same aspects of the disease. Clin-
ical outcome parameters may also be more sensitive to
placebo responses and thus combination of clinical out-
come measures with serum biomarkers may help to ob-
tain a consistent picture which can support go or no-go
decisions in proof-of-concept trials. A second aspect to
emphasize is that calprotectin, similar to CRP, is not ex-
clusively elevated in SpA but also in many other inflam-
matory conditions [44]. Comorbidity may influence
serum levels of calprotectin and CRP in SpA. Neverthe-
less, we demonstrated here that effective treatment still
induces rapid, robust and consistent changes in these
serum biomarkers, which are not observed during pla-
cebo treatment.
Our study has two important limitations. First, we used
a candidate approach based on a limited set of potential
biomarkers emerging from literature and/or insights into
tissue inflammation in SpA. However, a more systematic
approach using proteomics or gene expression arrays
allowing identification of novel biomarkers, therefore,
certainly remains warranted. For example, an unbiased
microarray analysis of peripheral blood cells could identify
a set of genes with expression that is closely correlated to
disease activity in AS; one of these genes codes for LIGHT
and serum levels of LIGHT have been confirmed to cor-
relate with CRP and erythrocyte sedimentation rate (ESR)
[45]. Second, we focused on the use of serum biomarkers
in a very specific setting, namely the measurement of bio-
logical impact on inflammation in PoC trials. The set-up
and size of the studies used in our analyses do not allow
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CRP levels not only reflect treatment response at the
group level but also allow discrimination at the individual
level of responders from non-responders to TNF block-
ade. Moreover, it remains unknown whether serum bio-
markers such as calprotectin may also reflect other
important clinical features of SpA. As, for example, both
CRP and VEGF serum levels correlate with osteoproli-
feration in axial SpA [46,47], it would be interesting to
explore the value of calprotectin in similar settings. Fi-
nally, we did not explore the value of calprotectin as a
biomarker of early disease, including non-radiographic
axial SpA and patients presenting with early inflamma-
tory back pain.
Conclusions
In summary, good biomarkers are needed in the develop-
ment of novel therapies in SpA to provide quick go and
no-go signals for PoC trials. Our data indicate that calpro-
tectin and CRP perform well as serum biomarkers, as
these biomarkers have a high sensitivity to change upon
clinical effective treatment and could be of use in the de-
velopment of new treatments.
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